One IV bag. One edit. That's the entire HAE pitch for Intellia's lonvo-z. The plumbing, in three steps: → lipid nanoparticles carry CRISPR to the liver → CRISPR knocks out the KLKB1 gene → less prekallikrein → less bradykinin → fewer swelling attacks Phase 3 HAELO: one 50 mg infusion cut mean monthly attacks ~87% vs placebo (weeks 5–28). FDA accepted the BLA with priority review on Sept 8. PDUFA: March 10, 2027. Current HAE prevention = lifelong injections or daily pills. A permanent edit means no refills. It also means no undo button, so long-term safety follow-up is where this gets decided. If approved, it would be the first in vivo CRISPR therapy. $NTLA gets the crown, $CRSP gave them the script. $BEAM $PRME $SCTX i.e. the future of gene-editing should all benefit from positive news flows in a complex industry that’s had its fair share of ups and downs.